作者
Lucile Vanhersecke,Maxime Brunet,Jean-Philippe Guégan,Christophe Rey,Antoine Bougoüin,Sophie Cousin,Sylvestre Le Moulec,Benjamin Besse,Yohann Loriot,Mathieu Larroquette,Isabelle Soubeyran,Maud Toulmonde,Guilhem Roubaud,Simon Pernot,Mathilde Cabart,François Chomy,Corentin Lefevre,Kévin Bourcier,Michèle Kind,Ilenia Giglioli,Catheriné Sautès-Fridman,Valérie Velasco,Félicie Courgeon,Ezoglin Oflazoglu,Ariel Savina,Aurélien Marabelle,Jean‐Charles Soria,C. Bellera,Casimir Ledoux Sofeu,Alban Bessede,Catheriné Sautès-Fridman,François Le Loarer,Antoîne Italiano
摘要
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.